Fig. 5.

Effect of PLIN5-S155A on lipid metabolism in livers of mice. A: Representative immunoblot showing PLIN5 and PLIN5-S155A re-expression in the livers of Plin5^−/− mice. Quantification of immunoblot shown to the right. B: PLIN5 content in the heart, kidney, and brown (BAT) and white (WAT) adipose tissue of mice. Quantification of immunoblot shown to the right. Representative immunoblotting shows n = 3 per group, n = 7 per group for quantification. C–H: Fatty acid metabolism was assessed in precision-cut liver slices ex vivo. C: ¹⁴C-fatty acid incorporation into triglyceride (TAG) as a percentage of ¹⁴C-fatty acid in all lipids (at the end of the “pulse” period). Specific activity in triglycerides calculated as total cpm in triglyceride divided by moles of triglyceride (D), fatty acid remaining in TAG (E), diglycerides (DAG) (F), and all other lipids at the end of the “chase” period (G). H: Oxidation of fatty acids derived from TAG determined during the “chase” period. De novo lipogenesis (I), liver triglyceride content assessed by biochemical analysis (J), triglyceride secretion from precision-cut liver slices (K), plasma triglycerides in mice (L), plasma free fatty acids (FFA) (M), and plasma β-hydroxybutyrate levels in mice (N). For all panels, AAV-PLIN5 n = 7, AAV-S155A n = 7. For panels (A–N), unpaired two-tailed t test was performed. ∗ P < 0.05 AAV-PLIN5 versus AAV-S155A.